WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) today issued financial and operational results for its fiscal second quarter ended June 30, 2014.
“The utilization of our PerioPredict™ genetic test in the dental office is progressing well as a result of the education approach we have used,” said Dr. Kenneth Kornman, Chief Executive Officer of Interleukin Genetics. “Adoption appears to be especially high at dental offices where ten or more patients have insurance plans that cover the test. This is important information for us to have as we continue our work supporting the education of dental offices about how to use the test to enhance dental preventative care. We continue to actively pursue new payer partners and work toward expanding the network of insurers who offer coverage for a risk-based preventative dental program.”
Help employers find you! Check out all the jobs and post your resume.
